Internal Medicine Journal最新文献

Background: Clozapine has demonstrated superiority in improving both positive and negative symptoms of treatment-resistant schizophrenia; however, there are associated treatment-limiting side effects, including myocarditis, cardiomyopathy and agranulocytosis.

Aim: This retrospective cohort study describes the prevalence of myocarditis, left ventricular (LV) dysfunction, cardiovascular risk factors and outcomes in a cohort of patients maintained on clozapine therapy.

Methods: Data were retrospectively collated from patients who had a diagnosis of schizophrenia, had been managed with clozapine at any stage during their care and undergone at least one echocardiogram.

Results: Between March 2020 and September 2021 674 patients were identified, 71% were male, with a mean age of 47 years old (interquartile range (IQR) 40-57). The mean duration of clozapine use was 7 years (IQR 4-13). The overall mortality was 5.54% during the follow-up period. Myocarditis was identified in one patient (0.15%) within the first 30 days, and an additional five cases were identified over the follow-up period (0.89%). The combined incidence of heart failure (HF) and myocarditis was 1.6% during the follow-up period. There was no association between LV size and function at baseline or during follow-up and adverse cardiac outcomes (comprising death, myocarditis, HF). Older age at initiation of therapy and baseline E/e' ratio were associated with risk of HF and myocarditis.

Conclusion: The overall incidence of myocarditis and HF during follow-up was low, with surveillance echocardiography offering limited predictive value. Patients maintained on clozapine are at risk of significant cardiovascular sequelae, likely reflecting an adverse risk factor profile.

Background: Neonatal and puerperal sepsis are major manifestations of invasive group B streptococcal (Streptococcus agalactiae; iGBS) infections. International data indicate the importance of iGBS infections among non-pregnant adults.

Aims: To describe the burden of iGBS infections in Western Australia (WA) between 2000 and 2018 in terms of incidence, length of hospitalisation and all-cause 30- and 90-day mortality.

Methods: This was a retrospective, population-based study using linked data from the state government-owned pathology provider, hospitalisations and death registrations. Children and adults with isolation of GBS in a normally sterile site or a hospital-based diagnosis of iGBS infection were included.

Results: There were 2861 cases; just over a quarter (n = 768) were aged 0-1 year. Half of the cases were among females (1438 of 2861), and the median age was 39 years. Incidence increased over the study period, with an age- and sex-adjusted incidence rate ratio for year of 1.08 (95% confidence interval (CI) 1.06-1.09). The incidence in 2018 was 9.5 cases (95% CI 8.3-10.6 cases) per 100 000 population. The proportion of cases among those aged 0-1 year fell across the period, while the relative incidence in older age groups increased. The median length of hospital stay was 7 days (interquartile range 4-15 days), and mortality at 30 days was 3% (95 of 2861).

Conclusions: iGBS cases increased across the period 2000-2018 in WA, with older adults making up a higher proportion of cases over time. Preventive efforts among older patients, including potentially through vaccination, may reverse this increase.

Background: Frailty is a recognisable clinical measure of impaired physiological reserve and vulnerability to adverse outcomes that is validated among patients with kidney disease. Practice patterns reveal inconsistent use of objective frailty measures by nephrologists, with clinicians prioritising subjective clinical impressions, possibly risking misclassification and discrimination.

Aims: The aim of this study was to examine correlations between subjective and objective measures of frailty in a cohort of patients attending routine nephrologist review.

Methods: Eighty-nine participants attending scheduled review with their primary treating nephrologist (n = 6) were included in cross-sectional analysis. Measured frailty based on Fried phenotype and subjective clinician impression were assessed for congruence using Pearson's correlation analysis and ĸ statistic. Ordinal logistic regression examined patient demographics associated with perceived frailty. Misclassification was explored using descriptive statistics and contingency table analysis.

Results: Frailty and prefrailty were prevalent by both objective and subjective means of assessment with minimal correlation between clinician impression and measured Fried phenotype (r = 0.50, P = 0.00, ĸ = 0.25, P = 0.00). Subjective clinician impression misclassified half of participants, influenced by surrogate frailty measures including female sex, comorbidity and reliance on a walking aid. Clinicians were equally likely to over-classify prefrailty as to under-recognise established frailty, with no evidence of systemic misclassification bias. Subjective clinican impression of frailty had a positive predictive value of 19.1% and a negative predictive value of 56.2%.

Conclusions: Nephrologists' reliance on subjective clinical impressions that overlook or misclassify prefrailty offers incomplete prognostic assessment and potentially misses opportunities for early intervention.

Medical misinformation (false health or medical-related information) has seen a rapid increase in volume recently, with the global surge in social media usage and further exacerbation by the COVID-19 pandemic. This may put more lives at stake, as misinformation is an often-cited reason that people make dangerous health choices, engage in harmful practices and reject beneficial health treatments. In this article, we explore the drivers and consequences, as well as suggest several strategies at the personal, educational and systemic level, for physicians to guide and communicate with patients who subscribe to medical misinformation.

Background: The Australian Rheumatology Association identified the use of imaging in patients with low back pain without indication of serious pathology as a low-value practice.

Aims: To determine the appropriateness of diagnostic lumbar spine imaging requests in patients with low back pain presenting to a Western Australian hospital's emergency department.

Methods: We conducted a retrospective review of all adult patients (18 years and older) who presented with low back pain to the Fiona Stanley Hospital emergency department from 1 July 2020 to 31 December 2020. The appropriateness of the imaging requests was judged using the American College of Radiology's Appropriateness Criteria. The number and proportion of appropriate and inappropriate lumbar spine imaging requests were reported overall and by imaging modality together with reasons for the judgements.

Results: A total of 1459 patients were included. Three hundred eight patients (21.1%) received lumbar spine imaging requests, with 350 diagnostic imaging requests eligible for analysis. Two hundred eighty (80.0%) imaging requests were judged to be appropriate (194/253 (76.7%) plain radiographs, 57/66 (86.4%) computed tomography, 29/31 (93.5%) magnetic resonance imaging). The most common reasons for an appropriate imaging request were suspected vertebral fracture (n = 223, 79.6%), followed by malignancy (n = 26, 9.3%). Of the 70 inappropriate imaging requests, 62 (88.6%) requests occurred in the absence of alerting features and eight (11.4%) requests were the wrong choice of modality.

Conclusions: Four in five lumbar spine imaging requests for investigating low back pain were appropriate. Of the inappropriate requests, the most common reason was the absence of alerting features, while a small number were the incorrect imaging modality.

Background: Cerebral microbleeds (CMBs) are small brain haemorrhages, identified by magnetic resonance imaging (MRI). They indicate potential for cognitive decline and mortality in memory clinic attendees. The presence of more than four CMBs is exclusionary for some clinical trials of disease-modifying therapies for Alzheimer's disease (AD). The prevalence and clinical relevance of CMBs in Australian memory clinic populations has not been reported.

Aims: To highlight the prevalence of CMBs in an Australian memory clinic cohort and explore associations with diagnoses, topography and cognitive performance.

Methods: We conducted a retrospective cohort study of 393 patients who attended a memory clinic (CDAMS) in Melbourne, Australia from January 2014 to December 2016 who underwent brain MRI. Data collected included age, gender, clinical diagnosis and cognitive scores. Univariable and multivariable regression analyses were performed to identify associations of CMBs with clinical and cognitive findings.

Results: The prevalence of CMBs was 27% (n=107) with good inter-rater reliability (κ=0.75). CMBs were significantly associated with increasing age. Prevalence of CMBs was higher in people with mild cognitive impairment (MCI) (32%) and dementia (39%) compared with other diagnostic groups (p<0.001). Lobar-predominant CMB distribution was associated with AD diagnosis. Presence of multiple CMBs was associated with poorer cognitive performance overall.

Conclusions: CMBs are common in an Australian memory clinic population and are associated with poorer cognitive performance. "Real world" prevalence of CMBs may limit accessibility to disease-modifying therapies for many people.

Enhancing patient comprehension of their health is crucial in improving health outcomes. The integration of artificial intelligence (AI) in distilling medical information into a conversational, legible format can potentially enhance health literacy. This review aims to examine the accuracy, reliability, comprehensiveness and readability of medical patient education materials (PEMs) simplified by AI models. A systematic review was conducted searching for articles assessing outcomes of use of AI in simplifying PEMs. Inclusion criteria are as follows: publication between January 2019 and June 2023, various modalities of AI, English language, AI use in PEMs and including physicians and/or patients. An inductive thematic approach was utilised to code for unifying topics which were qualitatively analysed. Twenty studies were included, and seven themes were identified (reproducibility, accessibility and ease of use, emotional support and user satisfaction, readability, data security, accuracy and reliability and comprehensiveness). AI effectively simplified PEMs, with reproducibility rates up to 90.7% in specific domains. User satisfaction exceeded 85% in AI-generated materials. AI models showed promising readability improvements, with ChatGPT achieving 100% post-simplification readability scores. AI's performance in accuracy and reliability was mixed, with occasional lack of comprehensiveness and inaccuracies, particularly when addressing complex medical topics. AI models accurately simplified basic tasks but lacked soft skills and personalisation. These limitations can be addressed with higher-calibre models combined with prompt engineering. In conclusion, the literature reveals a scope for AI to enhance patient health literacy through medical PEMs. Further refinement is needed to improve AI's accuracy and reliability, especially when simplifying complex medical information.

Background: Fabry disease is a rare X-linked multisystem disease, with progressive proteinuric kidney disease contributing significantly to morbidity and mortality of these patients. Evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end-stage kidney disease in both diabetic and non-diabetic kidney disease.

Aim: Evaluate the effects of SGLT2I on kidney function and albuminuria in patients with Fabry disease.

Methods: Single-centre real-world case series reviewing electronic medical records of patients with Fabry disease who initiated therapy with dapagliflozin or empagliflozin (n = 11). Changes in urine albumin-creatinine ratio (uACR) and creatinine before and after treatment with SGLT2I were analysed using Wilcoxon signed-rank test. Two-tailed P-values <0.05 were considered significant.

Results: Eleven patients were followed for up to 19 months after commencement of SGLT2I. An overall significant reduction in albuminuria (P = 0.05) was seen with SGLT2I use in the Fabry cohort. Median uACR before SGLT2I was 76 mg/mmol (interquartile range (IQR) 47-141) and after SGLT2I was 39 mg/mmol (IQR 18-95) (P = 0.05). All patients with uACR >100 mg/mmol had reduction in albuminuria over the study period. SGLT2Is were well tolerated overall, with only one case resulting in cessation of treatment due to adverse effects.

Conclusion: These results suggest SGLT2Is can significantly reduce albuminuria in a portion of patients with Fabry-related kidney disease and offer additional treatment for Fabry nephropathy. Given the nature of the study design and small case numbers, further long-term controlled studies are required to evaluate the long-term efficacy of this medication class in both cardiac and renal outcomes in Fabry disease.